Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients.
暂无分享,去创建一个
A. Pileri | G. Bonadonna | M. Di Nicola | S. Siena | A. Gianni | M. Bregni | M. Magni | F. Lombardi | C. Tarella | M. Nicola | Salvatore Siena
[1] G. Bonadonna,et al. Prolonged disease-free survival after high-dose sequential chemo-radiotherapy and haemopoietic autologous transplantation in poor prognosis Hodgkin's disease. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] P. Lansdorp,et al. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. , 1991, Blood.
[3] Edward J. Lee,et al. Etoposide. Current and future status , 1991, Cancer.
[4] A. Pileri,et al. Peripheral blood expansion of early progenitor cells after high-dose cyclophosphamide and rhGM-CSF. , 1991, European journal of cancer.
[5] R. Herzig. High‐dose etoposide and marrow transplantation , 1991, Cancer.
[6] R. Herzig,et al. High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy. , 1990, Blood.
[7] H. Lazarus,et al. Infusion of high doses of undiluted etoposide through central venous catheters during preparation for bone marrow transplantation. , 1990, Cancer investigation.
[8] A. Pileri,et al. GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR TO HARVEST CIRCULATING HAEMOPOIETIC STEM CELLS FOR AUTOTRANSPLANTATION , 1989, The Lancet.
[9] D G Lowe,et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] D. Amadori,et al. High-dose etoposide and autologous bone marrow transplantation as intensification treatment in small cell lung cancer: a pilot study. , 1989, Bone marrow transplantation.
[11] T. Barbui,et al. Early responder myeloma: kinetic studies identify a patient subgroup characterized by very poor prognosis. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] J. Gabrilove,et al. Effect of Granulocyte Colony-Stimulating Factor on Neutropenia and Associated Morbidity Due to Chemotherapy for Transitional-Cell Carcinoma of the Urothelium , 1989 .
[13] M. Socinski,et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. , 1988, The New England journal of medicine.
[14] B. Kushner,et al. Preclinical assessment of purging with VP-16-213: key role for long-term marrow cultures. , 1987, Blood.
[15] N. Mulder,et al. High-dose teniposide for refractory malignancies: a phase I study. , 1986, Cancer treatment reports.
[16] R. Souhami,et al. High-dose cyclophosphamide in small-cell carcinoma of the lung. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] J. Connors,et al. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. , 1985, Annals of internal medicine.
[18] B. Barlogie,et al. Effective treatment of advanced multiple myeloma refractory to alkylating agents. , 1984, The New England journal of medicine.
[19] J. Hainsworth,et al. High-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: a phase I study. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] J. Hainsworth,et al. High-dose etoposide as single-agent chemotherapy for small cell carcinoma of the lung. , 1983, Cancer treatment reports.
[21] J. Ducore,et al. Effects of the epipodophyllotoxin VP-16-213 on cell cycle traverse, DNA synthesis, and DNA strand size in cultures of human leukemic lymphoblasts. , 1983, Cancer research.